Valion Bio Terminates CEO, Expands CFO Role to COO

Company: Valion Bio · Event Type: CEO Termination + Leadership Restructuring · Filing: SEC Form 8-K, Item 5.02 · Effective Date: August 16, 2026 · Filed: August 17, 2026 Summary Valion Bio disclosed that Michael K. Handley was terminated as chief executive officer effective August…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal